Serum Metabolites and Kidney Outcomes: The Atherosclerosis Risk in Communities Study.
1,5-anhydroglucitrol
1-Linoleoylglycerophosphocholine
5-oxoproline
CKD progression
end-stage kidney disease
gamma-glutamylthreonine
gamma-glutamyltyrosine
glucose
kidney failure
mannose
metabolic pathways
metabolomics
Journal
Kidney medicine
ISSN: 2590-0595
Titre abrégé: Kidney Med
Pays: United States
ID NLM: 101756300
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
2
9
2022
Statut:
epublish
Résumé
Novel metabolite biomarkers of kidney failure with replacement therapy (KFRT) may help identify people at high risk for adverse kidney outcomes and implicated pathways may aid in developing targeted therapeutics. Prospective cohort. The cohort included 3,799 Atherosclerosis Risk in Communities study participants with serum samples available for measurement at visit 1 (1987-1989). Baseline serum levels of 318 metabolites. Incident KFRT, kidney failure (KFRT, estimated glomerular filtration rate <15 mL/min/1.73 m Because metabolites are often intercorrelated and represent shared pathways, we used a high dimension reduction technique called Netboost to cluster metabolites. Longitudinal associations between clusters of metabolites and KFRT and kidney failure were estimated using a Cox proportional hazards model. Mean age of study participants was 53 years, 61% were African American, and 13% had diabetes. There were 160 KFRT cases and 357 kidney failure cases over a mean of 23 years. The 314 metabolites were grouped in 43 clusters. Four clusters were significantly associated with risk of KFRT and 6 were associated with kidney failure (including 3 shared clusters). The 3 shared clusters suggested potential pathways perturbed early in kidney disease: cluster 5 (15 metabolites involved in alanine, aspartate, and glutamate metabolism as well as 5-oxoproline and several gamma-glutamyl amino acids), cluster 26 (6 metabolites involved in sugar and inositol phosphate metabolism), and cluster 34 (21 metabolites involved in glycerophospholipid metabolism). Several individual metabolites were also significantly associated with both KFRT and kidney failure, including glucose and mannose, which were associated with higher risk of both outcomes, and 5-oxoproline, gamma-glutamyl amino acids, linoleoylglycerophosphocholine, 1,5-anhydroglucitol, which were associated with lower risk of both outcomes. Inability to determine if the metabolites cause or are a consequence of changes in kidney function. We identified several clusters of metabolites reproducibly associated with development of KFRT. Future experimental studies are needed to validate our findings as well as continue unraveling metabolic pathways involved in kidney function decline.
Identifiants
pubmed: 36046612
doi: 10.1016/j.xkme.2022.100522
pii: S2590-0595(22)00144-3
pmc: PMC9420957
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100522Informations de copyright
© 2022 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.
Références
IEEE/ACM Trans Comput Biol Bioinform. 2021 Nov-Dec;18(6):2635-2648
pubmed: 32365034
Am J Med. 2016 Feb;129(2):153-162.e7
pubmed: 26391748
Am J Epidemiol. 2017 Oct 15;186(8):952-960
pubmed: 28535187
Clin Chem Lab Med. 2016 Jan;54(1):73-9
pubmed: 26124058
Nefrologia. 2017 May - Jun;37(3):267-275
pubmed: 28648203
J Clin Endocrinol Metab. 2016 Feb;101(2):696-704
pubmed: 26684276
Biochem Biophys Res Commun. 2014 Oct 17;453(2):220-8
pubmed: 24931670
J Am Soc Nephrol. 2018 Jun;29(6):1588-1590
pubmed: 29724883
Am J Kidney Dis. 2015 Aug;66(2):231-9
pubmed: 25773483
Kidney Int. 2017 Jan;91(1):61-69
pubmed: 27692817
Sci Rep. 2018 Feb 1;8(1):2133
pubmed: 29391561
Nat Genet. 2020 Feb;52(2):167-176
pubmed: 31959995
Diabetes Care. 2017 Mar;40(3):383-390
pubmed: 28087576
Chem Biol Interact. 1998 Apr 24;111-112:113-21
pubmed: 9679548
Sci Rep. 2020 Sep 29;10(1):16005
pubmed: 32994511
Anal Chem. 2009 Aug 15;81(16):6656-67
pubmed: 19624122
Am J Kidney Dis. 2020 Jan;75(1 Suppl 1):A6-A7
pubmed: 31704083
Diabetes. 2013 Feb;62(2):639-48
pubmed: 23043162
Mol Syst Biol. 2012;8:615
pubmed: 23010998
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):342-353
pubmed: 30733224
Kidney Int. 2019 Dec;96(6):1381-1388
pubmed: 31679767
Hypertension. 2013 Aug;62(2):398-403
pubmed: 23774226
Am J Kidney Dis. 2021 Jan;77(1):74-81
pubmed: 32971191
Kidney Int. 2014 May;85(5):1214-24
pubmed: 24429397
PLoS One. 2019 Mar 18;14(3):e0213764
pubmed: 30883578
Diabetes Care. 2016 Jun;39(6):988-95
pubmed: 27208342
Sci Rep. 2020 Jul 15;10(1):11668
pubmed: 32669624
Biochim Biophys Acta. 1996 Aug 29;1291(1):89-95
pubmed: 8781530
Am J Physiol Renal Physiol. 2007 Oct;293(4):F1256-61
pubmed: 17670904
Am J Epidemiol. 2013 Aug 15;178(4):534-42
pubmed: 23788672
J Am Coll Cardiol. 2021 Jun 15;77(23):2939-2959
pubmed: 34112321
Nat Rev Dis Primers. 2015 Jul 30;1:15018
pubmed: 27188921
Toxicol Pathol. 2009 Jun;37(4):521-35
pubmed: 19458390
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Arch Intern Med. 2009 Feb 23;169(4):342-50
pubmed: 19237717
Am J Kidney Dis. 2018 Mar;71(3 Suppl 1):A7
pubmed: 29477157
Sci Rep. 2020 Jun 22;10(1):10018
pubmed: 32572055
J Am Soc Nephrol. 2013 Jul;24(8):1330-8
pubmed: 23687356
Nephrol Dial Transplant. 2006 Sep;21(9):2446-51
pubmed: 16766542
Kidney Int. 2014 Jan;85(1):103-11
pubmed: 24048377
PLoS One. 2018 Apr 23;13(4):e0195172
pubmed: 29684044
Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1410-7
pubmed: 25011442
Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1787-1794
pubmed: 28971980
J Biol Chem. 1985 Jun 25;260(12):7304-8
pubmed: 3997870
Kidney Int Suppl. 2008 Dec;(111):S64-6
pubmed: 19034330
Lancet. 1992 Mar 7;339(8793):572-5
pubmed: 1347093
J Am Soc Nephrol. 2019 Jan;30(1):127-135
pubmed: 30559143
Neurology. 2019 Apr 16;92(16):e1890-e1898
pubmed: 30867269
J Am Soc Nephrol. 2018 Jul;29(7):1939-1947
pubmed: 29777021